Correlation between aggregated molecular cancer subtypes and selected clinical features
Colon Adenocarcinoma (Primary solid tumor)
16 April 2014  |  analyses__2014_04_16
Maintainer Information
Citation Information
Maintained by TCGA GDAC Team (Broad Institute/MD Anderson Cancer Center/Harvard Medical School)
Cite as Broad Institute TCGA Genome Data Analysis Center (2014): Correlation between aggregated molecular cancer subtypes and selected clinical features. Broad Institute of MIT and Harvard. doi:10.7908/C15X27H9
Overview
Introduction

This pipeline computes the correlation between cancer subtypes identified by different molecular patterns and selected clinical features.

Summary

Testing the association between subtypes identified by 12 different clustering approaches and 11 clinical features across 434 patients, 18 significant findings detected with P value < 0.05 and Q value < 0.25.

  • CNMF clustering analysis on array-based mRNA expression data identified 4 subtypes that correlate to 'HISTOLOGICAL.TYPE'.

  • Consensus hierarchical clustering analysis on array-based mRNA expression data identified 3 subtypes that correlate to 'HISTOLOGICAL.TYPE'.

  • 3 subtypes identified in current cancer cohort by 'Copy Number Ratio CNMF subtypes'. These subtypes correlate to 'PATHOLOGY.N.STAGE' and 'HISTOLOGICAL.TYPE'.

  • 3 subtypes identified in current cancer cohort by 'METHLYATION CNMF'. These subtypes correlate to 'AGE'.

  • CNMF clustering analysis on RPPA data identified 4 subtypes that do not correlate to any clinical features.

  • Consensus hierarchical clustering analysis on RPPA data identified 4 subtypes that do not correlate to any clinical features.

  • CNMF clustering analysis on sequencing-based mRNA expression data identified 5 subtypes that correlate to 'PATHOLOGY.M.STAGE' and 'HISTOLOGICAL.TYPE'.

  • Consensus hierarchical clustering analysis on sequencing-based mRNA expression data identified 3 subtypes that correlate to 'AGE',  'PATHOLOGY.M.STAGE',  'HISTOLOGICAL.TYPE', and 'COMPLETENESS.OF.RESECTION'.

  • 3 subtypes identified in current cancer cohort by 'MIRSEQ CNMF'. These subtypes correlate to 'AGE',  'PATHOLOGY.M.STAGE', and 'COMPLETENESS.OF.RESECTION'.

  • 3 subtypes identified in current cancer cohort by 'MIRSEQ CHIERARCHICAL'. These subtypes correlate to 'AGE',  'PATHOLOGY.M.STAGE', and 'COMPLETENESS.OF.RESECTION'.

  • 3 subtypes identified in current cancer cohort by 'MIRseq Mature CNMF subtypes'. These subtypes correlate to 'HISTOLOGICAL.TYPE'.

  • 3 subtypes identified in current cancer cohort by 'MIRseq Mature cHierClus subtypes'. These subtypes do not correlate to any clinical features.

Results
Overview of the results

Table 1.  Get Full Table Overview of the association between subtypes identified by 12 different clustering approaches and 11 clinical features. Shown in the table are P values (Q values). Thresholded by P value < 0.05 and Q value < 0.25, 18 significant findings detected.

Clinical
Features
Time
to
Death
AGE NEOPLASM
DISEASESTAGE
PATHOLOGY
T
STAGE
PATHOLOGY
N
STAGE
PATHOLOGY
M
STAGE
GENDER HISTOLOGICAL
TYPE
RADIATIONS
RADIATION
REGIMENINDICATION
COMPLETENESS
OF
RESECTION
NUMBER
OF
LYMPH
NODES
Statistical Tests logrank test ANOVA Chi-square test Chi-square test Chi-square test Chi-square test Fisher's exact test Fisher's exact test Fisher's exact test Chi-square test ANOVA
mRNA CNMF subtypes 0.496
(1.00)
0.569
(1.00)
0.00763
(0.816)
0.739
(1.00)
0.0121
(1.00)
0.0507
(1.00)
0.0361
(1.00)
1.24e-05
(0.0015)
0.204
(1.00)
0.104
(1.00)
mRNA cHierClus subtypes 0.155
(1.00)
0.0116
(1.00)
0.268
(1.00)
0.468
(1.00)
0.741
(1.00)
0.699
(1.00)
0.19
(1.00)
1.87e-07
(2.37e-05)
0.454
(1.00)
0.988
(1.00)
Copy Number Ratio CNMF subtypes 0.927
(1.00)
0.324
(1.00)
0.0119
(1.00)
0.466
(1.00)
0.000937
(0.109)
0.0066
(0.719)
0.404
(1.00)
1.01e-09
(1.32e-07)
0.185
(1.00)
0.0948
(1.00)
0.221
(1.00)
METHLYATION CNMF 0.994
(1.00)
0.000451
(0.0532)
0.388
(1.00)
0.351
(1.00)
0.812
(1.00)
0.268
(1.00)
0.0746
(1.00)
0.00882
(0.935)
0.479
(1.00)
0.29
(1.00)
0.773
(1.00)
RPPA CNMF subtypes 0.669
(1.00)
0.847
(1.00)
0.168
(1.00)
0.489
(1.00)
0.522
(1.00)
0.081
(1.00)
0.822
(1.00)
0.0364
(1.00)
0.5
(1.00)
0.00433
(0.48)
0.121
(1.00)
RPPA cHierClus subtypes 0.0823
(1.00)
0.376
(1.00)
0.316
(1.00)
0.355
(1.00)
0.18
(1.00)
0.175
(1.00)
0.261
(1.00)
0.268
(1.00)
0.32
(1.00)
0.217
(1.00)
0.0461
(1.00)
RNAseq CNMF subtypes 0.0434
(1.00)
0.00673
(0.727)
0.0281
(1.00)
0.495
(1.00)
0.00434
(0.48)
0.00106
(0.122)
0.105
(1.00)
9.33e-09
(1.2e-06)
0.358
(1.00)
0.00331
(0.37)
0.0337
(1.00)
RNAseq cHierClus subtypes 0.801
(1.00)
0.000782
(0.0914)
0.0401
(1.00)
0.947
(1.00)
0.346
(1.00)
3.07e-07
(3.87e-05)
0.172
(1.00)
0.00216
(0.244)
0.0641
(1.00)
4.26e-08
(5.45e-06)
0.525
(1.00)
MIRSEQ CNMF 0.211
(1.00)
0.000278
(0.0331)
0.167
(1.00)
0.358
(1.00)
0.312
(1.00)
1.02e-05
(0.00125)
0.441
(1.00)
0.095
(1.00)
0.07
(1.00)
7.93e-06
(0.000975)
0.0625
(1.00)
MIRSEQ CHIERARCHICAL 0.321
(1.00)
0.00212
(0.242)
0.0107
(1.00)
0.659
(1.00)
0.0252
(1.00)
2.16e-06
(0.00027)
0.312
(1.00)
1
(1.00)
0.597
(1.00)
7.85e-06
(0.000973)
0.524
(1.00)
MIRseq Mature CNMF subtypes 0.161
(1.00)
0.122
(1.00)
0.466
(1.00)
0.205
(1.00)
0.0279
(1.00)
0.459
(1.00)
0.312
(1.00)
6.9e-05
(0.00828)
0.744
(1.00)
0.45
(1.00)
0.042
(1.00)
MIRseq Mature cHierClus subtypes 0.204
(1.00)
0.157
(1.00)
0.947
(1.00)
0.723
(1.00)
0.419
(1.00)
0.86
(1.00)
0.865
(1.00)
0.0703
(1.00)
0.334
(1.00)
0.445
(1.00)
0.069
(1.00)
Clustering Approach #1: 'mRNA CNMF subtypes'

Table S1.  Description of clustering approach #1: 'mRNA CNMF subtypes'

Cluster Labels 1 2 3 4
Number of samples 38 61 30 24
'mRNA CNMF subtypes' versus 'Time to Death'

P value = 0.496 (logrank test), Q value = 1

Table S2.  Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #1: 'Time to Death'

nPatients nDeath Duration Range (Median), Month
ALL 121 25 0.9 - 54.0 (22.0)
subtype1 33 7 0.9 - 46.6 (23.4)
subtype2 45 12 1.0 - 51.0 (21.0)
subtype3 23 4 1.0 - 54.0 (17.0)
subtype4 20 2 0.9 - 50.0 (27.0)

Figure S1.  Get High-res Image Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #1: 'Time to Death'

'mRNA CNMF subtypes' versus 'AGE'

P value = 0.569 (ANOVA), Q value = 1

Table S3.  Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 153 70.8 (11.5)
subtype1 38 72.4 (11.4)
subtype2 61 69.9 (11.7)
subtype3 30 72.0 (10.9)
subtype4 24 68.9 (12.3)

Figure S2.  Get High-res Image Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #2: 'AGE'

'mRNA CNMF subtypes' versus 'NEOPLASM.DISEASESTAGE'

P value = 0.00763 (Chi-square test), Q value = 0.82

Table S4.  Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #3: 'NEOPLASM.DISEASESTAGE'

nPatients STAGE I STAGE II STAGE IIA STAGE IIB STAGE III STAGE IIIA STAGE IIIB STAGE IIIC STAGE IV STAGE IVA
ALL 29 12 45 5 8 3 12 16 21 1
subtype1 6 1 14 3 3 1 3 1 5 0
subtype2 11 2 12 0 2 2 5 13 14 0
subtype3 7 6 9 2 1 0 3 0 1 1
subtype4 5 3 10 0 2 0 1 2 1 0

Figure S3.  Get High-res Image Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #3: 'NEOPLASM.DISEASESTAGE'

'mRNA CNMF subtypes' versus 'PATHOLOGY.T.STAGE'

P value = 0.739 (Chi-square test), Q value = 1

Table S5.  Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #4: 'PATHOLOGY.T.STAGE'

nPatients T0+T1 T2 T3 T4
ALL 4 31 103 15
subtype1 1 7 24 6
subtype2 2 12 42 5
subtype3 0 7 19 4
subtype4 1 5 18 0

Figure S4.  Get High-res Image Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #4: 'PATHOLOGY.T.STAGE'

'mRNA CNMF subtypes' versus 'PATHOLOGY.N.STAGE'

P value = 0.0121 (Chi-square test), Q value = 1

Table S6.  Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #5: 'PATHOLOGY.N.STAGE'

nPatients N0 N1 N2
ALL 94 28 31
subtype1 25 5 8
subtype2 27 15 19
subtype3 24 5 1
subtype4 18 3 3

Figure S5.  Get High-res Image Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #5: 'PATHOLOGY.N.STAGE'

'mRNA CNMF subtypes' versus 'PATHOLOGY.M.STAGE'

P value = 0.0507 (Chi-square test), Q value = 1

Table S7.  Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #6: 'PATHOLOGY.M.STAGE'

nPatients M0 M1 M1A
ALL 129 21 1
subtype1 32 5 0
subtype2 47 14 0
subtype3 28 1 1
subtype4 22 1 0

Figure S6.  Get High-res Image Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #6: 'PATHOLOGY.M.STAGE'

'mRNA CNMF subtypes' versus 'GENDER'

P value = 0.0361 (Fisher's exact test), Q value = 1

Table S8.  Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #7: 'GENDER'

nPatients FEMALE MALE
ALL 75 78
subtype1 25 13
subtype2 31 30
subtype3 10 20
subtype4 9 15

Figure S7.  Get High-res Image Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #7: 'GENDER'

'mRNA CNMF subtypes' versus 'HISTOLOGICAL.TYPE'

P value = 1.24e-05 (Fisher's exact test), Q value = 0.0015

Table S9.  Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #8: 'HISTOLOGICAL.TYPE'

nPatients COLON ADENOCARCINOMA COLON MUCINOUS ADENOCARCINOMA
ALL 129 22
subtype1 25 13
subtype2 60 1
subtype3 22 7
subtype4 22 1

Figure S8.  Get High-res Image Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #8: 'HISTOLOGICAL.TYPE'

'mRNA CNMF subtypes' versus 'NUMBER.OF.LYMPH.NODES'

P value = 0.104 (ANOVA), Q value = 1

Table S10.  Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #10: 'NUMBER.OF.LYMPH.NODES'

nPatients Mean (Std.Dev)
ALL 152 2.1 (4.5)
subtype1 38 2.7 (5.8)
subtype2 61 2.8 (4.8)
subtype3 29 0.7 (2.3)
subtype4 24 1.2 (2.6)

Figure S9.  Get High-res Image Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #10: 'NUMBER.OF.LYMPH.NODES'

Clustering Approach #2: 'mRNA cHierClus subtypes'

Table S11.  Description of clustering approach #2: 'mRNA cHierClus subtypes'

Cluster Labels 1 2 3
Number of samples 57 46 50
'mRNA cHierClus subtypes' versus 'Time to Death'

P value = 0.155 (logrank test), Q value = 1

Table S12.  Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #1: 'Time to Death'

nPatients nDeath Duration Range (Median), Month
ALL 121 25 0.9 - 54.0 (22.0)
subtype1 41 12 1.0 - 54.0 (17.8)
subtype2 41 9 0.9 - 53.0 (22.0)
subtype3 39 4 0.9 - 47.0 (25.0)

Figure S10.  Get High-res Image Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #1: 'Time to Death'

'mRNA cHierClus subtypes' versus 'AGE'

P value = 0.0116 (ANOVA), Q value = 1

Table S13.  Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 153 70.8 (11.5)
subtype1 57 71.8 (9.4)
subtype2 46 73.7 (10.8)
subtype3 50 67.0 (13.4)

Figure S11.  Get High-res Image Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #2: 'AGE'

'mRNA cHierClus subtypes' versus 'NEOPLASM.DISEASESTAGE'

P value = 0.268 (Chi-square test), Q value = 1

Table S14.  Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #3: 'NEOPLASM.DISEASESTAGE'

nPatients STAGE I STAGE II STAGE IIA STAGE IIB STAGE III STAGE IIIA STAGE IIIB STAGE IIIC STAGE IV STAGE IVA
ALL 29 12 45 5 8 3 12 16 21 1
subtype1 7 7 16 1 3 2 3 9 8 1
subtype2 9 3 14 4 3 1 5 1 5 0
subtype3 13 2 15 0 2 0 4 6 8 0

Figure S12.  Get High-res Image Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #3: 'NEOPLASM.DISEASESTAGE'

'mRNA cHierClus subtypes' versus 'PATHOLOGY.T.STAGE'

P value = 0.468 (Chi-square test), Q value = 1

Table S15.  Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #4: 'PATHOLOGY.T.STAGE'

nPatients T0+T1 T2 T3 T4
ALL 4 31 103 15
subtype1 1 8 43 5
subtype2 1 10 28 7
subtype3 2 13 32 3

Figure S13.  Get High-res Image Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #4: 'PATHOLOGY.T.STAGE'

'mRNA cHierClus subtypes' versus 'PATHOLOGY.N.STAGE'

P value = 0.741 (Chi-square test), Q value = 1

Table S16.  Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #5: 'PATHOLOGY.N.STAGE'

nPatients N0 N1 N2
ALL 94 28 31
subtype1 33 13 11
subtype2 31 7 8
subtype3 30 8 12

Figure S14.  Get High-res Image Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #5: 'PATHOLOGY.N.STAGE'

'mRNA cHierClus subtypes' versus 'PATHOLOGY.M.STAGE'

P value = 0.699 (Chi-square test), Q value = 1

Table S17.  Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #6: 'PATHOLOGY.M.STAGE'

nPatients M0 M1 M1A
ALL 129 21 1
subtype1 48 8 1
subtype2 40 5 0
subtype3 41 8 0

Figure S15.  Get High-res Image Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #6: 'PATHOLOGY.M.STAGE'

'mRNA cHierClus subtypes' versus 'GENDER'

P value = 0.19 (Fisher's exact test), Q value = 1

Table S18.  Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #7: 'GENDER'

nPatients FEMALE MALE
ALL 75 78
subtype1 28 29
subtype2 27 19
subtype3 20 30

Figure S16.  Get High-res Image Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #7: 'GENDER'

'mRNA cHierClus subtypes' versus 'HISTOLOGICAL.TYPE'

P value = 1.87e-07 (Fisher's exact test), Q value = 2.4e-05

Table S19.  Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #8: 'HISTOLOGICAL.TYPE'

nPatients COLON ADENOCARCINOMA COLON MUCINOUS ADENOCARCINOMA
ALL 129 22
subtype1 54 3
subtype2 27 18
subtype3 48 1

Figure S17.  Get High-res Image Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #8: 'HISTOLOGICAL.TYPE'

'mRNA cHierClus subtypes' versus 'NUMBER.OF.LYMPH.NODES'

P value = 0.988 (ANOVA), Q value = 1

Table S20.  Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #10: 'NUMBER.OF.LYMPH.NODES'

nPatients Mean (Std.Dev)
ALL 152 2.1 (4.5)
subtype1 56 2.2 (4.9)
subtype2 46 2.2 (4.7)
subtype3 50 2.1 (3.9)

Figure S18.  Get High-res Image Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #10: 'NUMBER.OF.LYMPH.NODES'

Clustering Approach #3: 'Copy Number Ratio CNMF subtypes'

Table S21.  Description of clustering approach #3: 'Copy Number Ratio CNMF subtypes'

Cluster Labels 1 2 3
Number of samples 170 195 60
'Copy Number Ratio CNMF subtypes' versus 'Time to Death'

P value = 0.927 (logrank test), Q value = 1

Table S22.  Clustering Approach #3: 'Copy Number Ratio CNMF subtypes' versus Clinical Feature #1: 'Time to Death'

nPatients nDeath Duration Range (Median), Month
ALL 385 81 0.1 - 140.4 (17.0)
subtype1 151 30 0.1 - 131.5 (17.0)
subtype2 179 39 0.1 - 140.4 (17.9)
subtype3 55 12 0.5 - 119.7 (13.9)

Figure S19.  Get High-res Image Clustering Approach #3: 'Copy Number Ratio CNMF subtypes' versus Clinical Feature #1: 'Time to Death'

'Copy Number Ratio CNMF subtypes' versus 'AGE'

P value = 0.324 (ANOVA), Q value = 1

Table S23.  Clustering Approach #3: 'Copy Number Ratio CNMF subtypes' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 424 67.2 (12.9)
subtype1 170 66.8 (12.0)
subtype2 194 68.1 (14.0)
subtype3 60 65.4 (11.5)

Figure S20.  Get High-res Image Clustering Approach #3: 'Copy Number Ratio CNMF subtypes' versus Clinical Feature #2: 'AGE'

'Copy Number Ratio CNMF subtypes' versus 'NEOPLASM.DISEASESTAGE'

P value = 0.0119 (Chi-square test), Q value = 1

Table S24.  Clustering Approach #3: 'Copy Number Ratio CNMF subtypes' versus Clinical Feature #3: 'NEOPLASM.DISEASESTAGE'

nPatients STAGE I STAGE IA STAGE II STAGE IIA STAGE IIB STAGE IIC STAGE III STAGE IIIA STAGE IIIB STAGE IIIC STAGE IV STAGE IVA STAGE IVB
ALL 71 1 33 120 8 1 22 13 52 36 42 16 1
subtype1 21 0 6 41 2 1 8 8 24 17 26 11 0
subtype2 38 1 19 66 6 0 10 3 20 14 10 3 1
subtype3 12 0 8 13 0 0 4 2 8 5 6 2 0

Figure S21.  Get High-res Image Clustering Approach #3: 'Copy Number Ratio CNMF subtypes' versus Clinical Feature #3: 'NEOPLASM.DISEASESTAGE'

'Copy Number Ratio CNMF subtypes' versus 'PATHOLOGY.T.STAGE'

P value = 0.466 (Chi-square test), Q value = 1

Table S25.  Clustering Approach #3: 'Copy Number Ratio CNMF subtypes' versus Clinical Feature #4: 'PATHOLOGY.T.STAGE'

nPatients T0+T1 T2 T3 T4
ALL 11 75 291 47
subtype1 5 25 123 17
subtype2 6 36 127 25
subtype3 0 14 41 5

Figure S22.  Get High-res Image Clustering Approach #3: 'Copy Number Ratio CNMF subtypes' versus Clinical Feature #4: 'PATHOLOGY.T.STAGE'

'Copy Number Ratio CNMF subtypes' versus 'PATHOLOGY.N.STAGE'

P value = 0.000937 (Chi-square test), Q value = 0.11

Table S26.  Clustering Approach #3: 'Copy Number Ratio CNMF subtypes' versus Clinical Feature #5: 'PATHOLOGY.N.STAGE'

nPatients N0 N1 N2
ALL 249 101 74
subtype1 79 53 37
subtype2 134 33 28
subtype3 36 15 9

Figure S23.  Get High-res Image Clustering Approach #3: 'Copy Number Ratio CNMF subtypes' versus Clinical Feature #5: 'PATHOLOGY.N.STAGE'

'Copy Number Ratio CNMF subtypes' versus 'PATHOLOGY.M.STAGE'

P value = 0.0066 (Chi-square test), Q value = 0.72

Table S27.  Clustering Approach #3: 'Copy Number Ratio CNMF subtypes' versus Clinical Feature #6: 'PATHOLOGY.M.STAGE'

nPatients M0 M1 M1A M1B MX
ALL 318 50 7 1 42
subtype1 114 32 5 0 16
subtype2 157 11 1 1 22
subtype3 47 7 1 0 4

Figure S24.  Get High-res Image Clustering Approach #3: 'Copy Number Ratio CNMF subtypes' versus Clinical Feature #6: 'PATHOLOGY.M.STAGE'

'Copy Number Ratio CNMF subtypes' versus 'GENDER'

P value = 0.404 (Fisher's exact test), Q value = 1

Table S28.  Clustering Approach #3: 'Copy Number Ratio CNMF subtypes' versus Clinical Feature #7: 'GENDER'

nPatients FEMALE MALE
ALL 199 226
subtype1 76 94
subtype2 98 97
subtype3 25 35

Figure S25.  Get High-res Image Clustering Approach #3: 'Copy Number Ratio CNMF subtypes' versus Clinical Feature #7: 'GENDER'

'Copy Number Ratio CNMF subtypes' versus 'HISTOLOGICAL.TYPE'

P value = 1.01e-09 (Fisher's exact test), Q value = 1.3e-07

Table S29.  Clustering Approach #3: 'Copy Number Ratio CNMF subtypes' versus Clinical Feature #8: 'HISTOLOGICAL.TYPE'

nPatients COLON ADENOCARCINOMA COLON MUCINOUS ADENOCARCINOMA
ALL 368 55
subtype1 165 4
subtype2 148 46
subtype3 55 5

Figure S26.  Get High-res Image Clustering Approach #3: 'Copy Number Ratio CNMF subtypes' versus Clinical Feature #8: 'HISTOLOGICAL.TYPE'

'Copy Number Ratio CNMF subtypes' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 0.185 (Fisher's exact test), Q value = 1

Table S30.  Clustering Approach #3: 'Copy Number Ratio CNMF subtypes' versus Clinical Feature #9: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients NO YES
ALL 3 422
subtype1 2 168
subtype2 0 195
subtype3 1 59

Figure S27.  Get High-res Image Clustering Approach #3: 'Copy Number Ratio CNMF subtypes' versus Clinical Feature #9: 'RADIATIONS.RADIATION.REGIMENINDICATION'

'Copy Number Ratio CNMF subtypes' versus 'COMPLETENESS.OF.RESECTION'

P value = 0.0948 (Chi-square test), Q value = 1

Table S31.  Clustering Approach #3: 'Copy Number Ratio CNMF subtypes' versus Clinical Feature #10: 'COMPLETENESS.OF.RESECTION'

nPatients R0 R1 R2 RX
ALL 298 3 24 24
subtype1 117 1 15 7
subtype2 141 2 4 14
subtype3 40 0 5 3

Figure S28.  Get High-res Image Clustering Approach #3: 'Copy Number Ratio CNMF subtypes' versus Clinical Feature #10: 'COMPLETENESS.OF.RESECTION'

'Copy Number Ratio CNMF subtypes' versus 'NUMBER.OF.LYMPH.NODES'

P value = 0.221 (ANOVA), Q value = 1

Table S32.  Clustering Approach #3: 'Copy Number Ratio CNMF subtypes' versus Clinical Feature #11: 'NUMBER.OF.LYMPH.NODES'

nPatients Mean (Std.Dev)
ALL 401 2.0 (4.5)
subtype1 163 2.5 (5.1)
subtype2 182 1.7 (4.2)
subtype3 56 1.6 (3.3)

Figure S29.  Get High-res Image Clustering Approach #3: 'Copy Number Ratio CNMF subtypes' versus Clinical Feature #11: 'NUMBER.OF.LYMPH.NODES'

Clustering Approach #4: 'METHLYATION CNMF'

Table S33.  Description of clustering approach #4: 'METHLYATION CNMF'

Cluster Labels 1 2 3
Number of samples 113 89 68
'METHLYATION CNMF' versus 'Time to Death'

P value = 0.994 (logrank test), Q value = 1

Table S34.  Clustering Approach #4: 'METHLYATION CNMF' versus Clinical Feature #1: 'Time to Death'

nPatients nDeath Duration Range (Median), Month
ALL 263 55 0.1 - 140.4 (15.0)
subtype1 108 24 0.1 - 140.4 (17.5)
subtype2 87 19 0.1 - 135.7 (15.0)
subtype3 68 12 0.1 - 102.4 (13.0)

Figure S30.  Get High-res Image Clustering Approach #4: 'METHLYATION CNMF' versus Clinical Feature #1: 'Time to Death'

'METHLYATION CNMF' versus 'AGE'

P value = 0.000451 (ANOVA), Q value = 0.053

Table S35.  Clustering Approach #4: 'METHLYATION CNMF' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 269 65.1 (13.1)
subtype1 113 65.9 (12.7)
subtype2 89 68.0 (12.7)
subtype3 67 60.0 (12.9)

Figure S31.  Get High-res Image Clustering Approach #4: 'METHLYATION CNMF' versus Clinical Feature #2: 'AGE'

'METHLYATION CNMF' versus 'NEOPLASM.DISEASESTAGE'

P value = 0.388 (Chi-square test), Q value = 1

Table S36.  Clustering Approach #4: 'METHLYATION CNMF' versus Clinical Feature #3: 'NEOPLASM.DISEASESTAGE'

nPatients STAGE I STAGE IA STAGE II STAGE IIA STAGE IIB STAGE IIC STAGE III STAGE IIIA STAGE IIIB STAGE IIIC STAGE IV STAGE IVA STAGE IVB
ALL 40 1 19 81 5 1 8 10 40 21 20 15 1
subtype1 15 0 7 31 1 1 4 5 16 8 11 10 0
subtype2 19 1 4 27 3 0 4 2 13 6 4 3 1
subtype3 6 0 8 23 1 0 0 3 11 7 5 2 0

Figure S32.  Get High-res Image Clustering Approach #4: 'METHLYATION CNMF' versus Clinical Feature #3: 'NEOPLASM.DISEASESTAGE'

'METHLYATION CNMF' versus 'PATHOLOGY.T.STAGE'

P value = 0.351 (Chi-square test), Q value = 1

Table S37.  Clustering Approach #4: 'METHLYATION CNMF' versus Clinical Feature #4: 'PATHOLOGY.T.STAGE'

nPatients T0+T1 T2 T3 T4
ALL 7 41 188 33
subtype1 3 18 80 12
subtype2 3 18 57 10
subtype3 1 5 51 11

Figure S33.  Get High-res Image Clustering Approach #4: 'METHLYATION CNMF' versus Clinical Feature #4: 'PATHOLOGY.T.STAGE'

'METHLYATION CNMF' versus 'PATHOLOGY.N.STAGE'

P value = 0.812 (Chi-square test), Q value = 1

Table S38.  Clustering Approach #4: 'METHLYATION CNMF' versus Clinical Feature #5: 'PATHOLOGY.N.STAGE'

nPatients N0 N1 N2
ALL 159 69 41
subtype1 63 31 18
subtype2 56 19 14
subtype3 40 19 9

Figure S34.  Get High-res Image Clustering Approach #4: 'METHLYATION CNMF' versus Clinical Feature #5: 'PATHOLOGY.N.STAGE'

'METHLYATION CNMF' versus 'PATHOLOGY.M.STAGE'

P value = 0.268 (Chi-square test), Q value = 1

Table S39.  Clustering Approach #4: 'METHLYATION CNMF' versus Clinical Feature #6: 'PATHOLOGY.M.STAGE'

nPatients M0 M1 M1A M1B MX
ALL 188 28 6 1 42
subtype1 72 17 4 0 19
subtype2 64 5 1 1 15
subtype3 52 6 1 0 8

Figure S35.  Get High-res Image Clustering Approach #4: 'METHLYATION CNMF' versus Clinical Feature #6: 'PATHOLOGY.M.STAGE'

'METHLYATION CNMF' versus 'GENDER'

P value = 0.0746 (Fisher's exact test), Q value = 1

Table S40.  Clustering Approach #4: 'METHLYATION CNMF' versus Clinical Feature #7: 'GENDER'

nPatients FEMALE MALE
ALL 122 148
subtype1 46 67
subtype2 49 40
subtype3 27 41

Figure S36.  Get High-res Image Clustering Approach #4: 'METHLYATION CNMF' versus Clinical Feature #7: 'GENDER'

'METHLYATION CNMF' versus 'HISTOLOGICAL.TYPE'

P value = 0.00882 (Fisher's exact test), Q value = 0.93

Table S41.  Clustering Approach #4: 'METHLYATION CNMF' versus Clinical Feature #8: 'HISTOLOGICAL.TYPE'

nPatients COLON ADENOCARCINOMA COLON MUCINOUS ADENOCARCINOMA
ALL 237 33
subtype1 107 6
subtype2 74 15
subtype3 56 12

Figure S37.  Get High-res Image Clustering Approach #4: 'METHLYATION CNMF' versus Clinical Feature #8: 'HISTOLOGICAL.TYPE'

'METHLYATION CNMF' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 0.479 (Fisher's exact test), Q value = 1

Table S42.  Clustering Approach #4: 'METHLYATION CNMF' versus Clinical Feature #9: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients NO YES
ALL 3 267
subtype1 2 111
subtype2 0 89
subtype3 1 67

Figure S38.  Get High-res Image Clustering Approach #4: 'METHLYATION CNMF' versus Clinical Feature #9: 'RADIATIONS.RADIATION.REGIMENINDICATION'

'METHLYATION CNMF' versus 'COMPLETENESS.OF.RESECTION'

P value = 0.29 (Chi-square test), Q value = 1

Table S43.  Clustering Approach #4: 'METHLYATION CNMF' versus Clinical Feature #10: 'COMPLETENESS.OF.RESECTION'

nPatients R0 R1 R2 RX
ALL 169 2 4 23
subtype1 71 0 3 8
subtype2 54 2 1 10
subtype3 44 0 0 5

Figure S39.  Get High-res Image Clustering Approach #4: 'METHLYATION CNMF' versus Clinical Feature #10: 'COMPLETENESS.OF.RESECTION'

'METHLYATION CNMF' versus 'NUMBER.OF.LYMPH.NODES'

P value = 0.773 (ANOVA), Q value = 1

Table S44.  Clustering Approach #4: 'METHLYATION CNMF' versus Clinical Feature #11: 'NUMBER.OF.LYMPH.NODES'

nPatients Mean (Std.Dev)
ALL 247 1.9 (4.4)
subtype1 104 2.1 (5.7)
subtype2 81 1.6 (3.0)
subtype3 62 1.9 (3.6)

Figure S40.  Get High-res Image Clustering Approach #4: 'METHLYATION CNMF' versus Clinical Feature #11: 'NUMBER.OF.LYMPH.NODES'

Clustering Approach #5: 'RPPA CNMF subtypes'

Table S45.  Description of clustering approach #5: 'RPPA CNMF subtypes'

Cluster Labels 1 2 3 4
Number of samples 80 128 27 96
'RPPA CNMF subtypes' versus 'Time to Death'

P value = 0.669 (logrank test), Q value = 1

Table S46.  Clustering Approach #5: 'RPPA CNMF subtypes' versus Clinical Feature #1: 'Time to Death'

nPatients nDeath Duration Range (Median), Month
ALL 303 63 0.1 - 140.4 (16.1)
subtype1 75 11 0.1 - 131.5 (16.0)
subtype2 113 29 0.1 - 140.4 (17.0)
subtype3 21 3 1.0 - 52.0 (17.8)
subtype4 94 20 0.1 - 135.7 (17.0)

Figure S41.  Get High-res Image Clustering Approach #5: 'RPPA CNMF subtypes' versus Clinical Feature #1: 'Time to Death'

'RPPA CNMF subtypes' versus 'AGE'

P value = 0.847 (ANOVA), Q value = 1

Table S47.  Clustering Approach #5: 'RPPA CNMF subtypes' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 330 67.3 (13.0)
subtype1 80 66.8 (12.9)
subtype2 127 68.1 (12.3)
subtype3 27 66.9 (11.9)
subtype4 96 66.7 (14.3)

Figure S42.  Get High-res Image Clustering Approach #5: 'RPPA CNMF subtypes' versus Clinical Feature #2: 'AGE'

'RPPA CNMF subtypes' versus 'NEOPLASM.DISEASESTAGE'

P value = 0.168 (Chi-square test), Q value = 1

Table S48.  Clustering Approach #5: 'RPPA CNMF subtypes' versus Clinical Feature #3: 'NEOPLASM.DISEASESTAGE'

nPatients STAGE I STAGE IA STAGE II STAGE IIA STAGE IIB STAGE IIC STAGE III STAGE IIIA STAGE IIIB STAGE IIIC STAGE IV STAGE IVA STAGE IVB
ALL 49 1 25 103 8 1 19 8 42 29 28 14 1
subtype1 10 0 9 20 3 0 2 3 14 10 5 4 0
subtype2 18 0 11 33 3 1 9 2 17 8 18 5 1
subtype3 3 1 1 12 0 0 2 0 3 3 1 1 0
subtype4 18 0 4 38 2 0 6 3 8 8 4 4 0

Figure S43.  Get High-res Image Clustering Approach #5: 'RPPA CNMF subtypes' versus Clinical Feature #3: 'NEOPLASM.DISEASESTAGE'

'RPPA CNMF subtypes' versus 'PATHOLOGY.T.STAGE'

P value = 0.489 (Chi-square test), Q value = 1

Table S49.  Clustering Approach #5: 'RPPA CNMF subtypes' versus Clinical Feature #4: 'PATHOLOGY.T.STAGE'

nPatients T0+T1 T2 T3 T4
ALL 6 53 233 38
subtype1 0 12 59 9
subtype2 2 21 90 15
subtype3 0 3 22 1
subtype4 4 17 62 13

Figure S44.  Get High-res Image Clustering Approach #5: 'RPPA CNMF subtypes' versus Clinical Feature #4: 'PATHOLOGY.T.STAGE'

'RPPA CNMF subtypes' versus 'PATHOLOGY.N.STAGE'

P value = 0.522 (Chi-square test), Q value = 1

Table S50.  Clustering Approach #5: 'RPPA CNMF subtypes' versus Clinical Feature #5: 'PATHOLOGY.N.STAGE'

nPatients N0 N1 N2
ALL 196 80 55
subtype1 42 23 15
subtype2 72 32 24
subtype3 17 6 4
subtype4 65 19 12

Figure S45.  Get High-res Image Clustering Approach #5: 'RPPA CNMF subtypes' versus Clinical Feature #5: 'PATHOLOGY.N.STAGE'

'RPPA CNMF subtypes' versus 'PATHOLOGY.M.STAGE'

P value = 0.081 (Chi-square test), Q value = 1

Table S51.  Clustering Approach #5: 'RPPA CNMF subtypes' versus Clinical Feature #6: 'PATHOLOGY.M.STAGE'

nPatients M0 M1 M1A M1B MX
ALL 259 36 6 1 26
subtype1 65 6 3 0 5
subtype2 92 23 0 1 11
subtype3 24 2 0 0 1
subtype4 78 5 3 0 9

Figure S46.  Get High-res Image Clustering Approach #5: 'RPPA CNMF subtypes' versus Clinical Feature #6: 'PATHOLOGY.M.STAGE'

'RPPA CNMF subtypes' versus 'GENDER'

P value = 0.822 (Fisher's exact test), Q value = 1

Table S52.  Clustering Approach #5: 'RPPA CNMF subtypes' versus Clinical Feature #7: 'GENDER'

nPatients FEMALE MALE
ALL 155 176
subtype1 38 42
subtype2 56 72
subtype3 13 14
subtype4 48 48

Figure S47.  Get High-res Image Clustering Approach #5: 'RPPA CNMF subtypes' versus Clinical Feature #7: 'GENDER'

'RPPA CNMF subtypes' versus 'HISTOLOGICAL.TYPE'

P value = 0.0364 (Fisher's exact test), Q value = 1

Table S53.  Clustering Approach #5: 'RPPA CNMF subtypes' versus Clinical Feature #8: 'HISTOLOGICAL.TYPE'

nPatients COLON ADENOCARCINOMA COLON MUCINOUS ADENOCARCINOMA
ALL 293 38
subtype1 68 12
subtype2 121 7
subtype3 23 4
subtype4 81 15

Figure S48.  Get High-res Image Clustering Approach #5: 'RPPA CNMF subtypes' versus Clinical Feature #8: 'HISTOLOGICAL.TYPE'

'RPPA CNMF subtypes' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 0.5 (Fisher's exact test), Q value = 1

Table S54.  Clustering Approach #5: 'RPPA CNMF subtypes' versus Clinical Feature #9: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients NO YES
ALL 3 328
subtype1 2 78
subtype2 1 127
subtype3 0 27
subtype4 0 96

Figure S49.  Get High-res Image Clustering Approach #5: 'RPPA CNMF subtypes' versus Clinical Feature #9: 'RADIATIONS.RADIATION.REGIMENINDICATION'

'RPPA CNMF subtypes' versus 'COMPLETENESS.OF.RESECTION'

P value = 0.00433 (Chi-square test), Q value = 0.48

Table S55.  Clustering Approach #5: 'RPPA CNMF subtypes' versus Clinical Feature #10: 'COMPLETENESS.OF.RESECTION'

nPatients R0 R2 RX
ALL 239 16 16
subtype1 60 1 6
subtype2 77 13 6
subtype3 26 1 0
subtype4 76 1 4

Figure S50.  Get High-res Image Clustering Approach #5: 'RPPA CNMF subtypes' versus Clinical Feature #10: 'COMPLETENESS.OF.RESECTION'

'RPPA CNMF subtypes' versus 'NUMBER.OF.LYMPH.NODES'

P value = 0.121 (ANOVA), Q value = 1

Table S56.  Clustering Approach #5: 'RPPA CNMF subtypes' versus Clinical Feature #11: 'NUMBER.OF.LYMPH.NODES'

nPatients Mean (Std.Dev)
ALL 311 2.0 (4.5)
subtype1 74 2.9 (6.8)
subtype2 120 2.0 (3.8)
subtype3 27 1.7 (3.3)
subtype4 90 1.2 (2.6)

Figure S51.  Get High-res Image Clustering Approach #5: 'RPPA CNMF subtypes' versus Clinical Feature #11: 'NUMBER.OF.LYMPH.NODES'

Clustering Approach #6: 'RPPA cHierClus subtypes'

Table S57.  Description of clustering approach #6: 'RPPA cHierClus subtypes'

Cluster Labels 1 2 3 4
Number of samples 29 57 64 181
'RPPA cHierClus subtypes' versus 'Time to Death'

P value = 0.0823 (logrank test), Q value = 1

Table S58.  Clustering Approach #6: 'RPPA cHierClus subtypes' versus Clinical Feature #1: 'Time to Death'

nPatients nDeath Duration Range (Median), Month
ALL 303 63 0.1 - 140.4 (16.1)
subtype1 24 9 2.0 - 107.7 (14.5)
subtype2 56 9 0.1 - 135.7 (18.7)
subtype3 63 7 0.1 - 131.5 (14.3)
subtype4 160 38 0.1 - 140.4 (17.5)

Figure S52.  Get High-res Image Clustering Approach #6: 'RPPA cHierClus subtypes' versus Clinical Feature #1: 'Time to Death'

'RPPA cHierClus subtypes' versus 'AGE'

P value = 0.376 (ANOVA), Q value = 1

Table S59.  Clustering Approach #6: 'RPPA cHierClus subtypes' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 330 67.3 (13.0)
subtype1 29 69.5 (13.4)
subtype2 57 65.3 (13.4)
subtype3 64 66.1 (12.1)
subtype4 180 67.9 (13.1)

Figure S53.  Get High-res Image Clustering Approach #6: 'RPPA cHierClus subtypes' versus Clinical Feature #2: 'AGE'

'RPPA cHierClus subtypes' versus 'NEOPLASM.DISEASESTAGE'

P value = 0.316 (Chi-square test), Q value = 1

Table S60.  Clustering Approach #6: 'RPPA cHierClus subtypes' versus Clinical Feature #3: 'NEOPLASM.DISEASESTAGE'

nPatients STAGE I STAGE IA STAGE II STAGE IIA STAGE IIB STAGE IIC STAGE III STAGE IIIA STAGE IIIB STAGE IIIC STAGE IV STAGE IVA STAGE IVB
ALL 49 1 25 103 8 1 19 8 42 29 28 14 1
subtype1 2 0 3 13 1 0 2 0 4 1 2 0 0
subtype2 14 0 3 22 1 0 2 1 4 5 2 3 0
subtype3 8 0 2 22 1 0 0 3 9 9 4 6 0
subtype4 25 1 17 46 5 1 15 4 25 14 20 5 1

Figure S54.  Get High-res Image Clustering Approach #6: 'RPPA cHierClus subtypes' versus Clinical Feature #3: 'NEOPLASM.DISEASESTAGE'

'RPPA cHierClus subtypes' versus 'PATHOLOGY.T.STAGE'

P value = 0.355 (Chi-square test), Q value = 1

Table S61.  Clustering Approach #6: 'RPPA cHierClus subtypes' versus Clinical Feature #4: 'PATHOLOGY.T.STAGE'

nPatients T0+T1 T2 T3 T4
ALL 6 53 233 38
subtype1 0 2 24 3
subtype2 3 13 35 6
subtype3 1 8 47 8
subtype4 2 30 127 21

Figure S55.  Get High-res Image Clustering Approach #6: 'RPPA cHierClus subtypes' versus Clinical Feature #4: 'PATHOLOGY.T.STAGE'

'RPPA cHierClus subtypes' versus 'PATHOLOGY.N.STAGE'

P value = 0.18 (Chi-square test), Q value = 1

Table S62.  Clustering Approach #6: 'RPPA cHierClus subtypes' versus Clinical Feature #5: 'PATHOLOGY.N.STAGE'

nPatients N0 N1 N2
ALL 196 80 55
subtype1 19 6 4
subtype2 42 9 6
subtype3 34 15 15
subtype4 101 50 30

Figure S56.  Get High-res Image Clustering Approach #6: 'RPPA cHierClus subtypes' versus Clinical Feature #5: 'PATHOLOGY.N.STAGE'

'RPPA cHierClus subtypes' versus 'PATHOLOGY.M.STAGE'

P value = 0.175 (Chi-square test), Q value = 1

Table S63.  Clustering Approach #6: 'RPPA cHierClus subtypes' versus Clinical Feature #6: 'PATHOLOGY.M.STAGE'

nPatients M0 M1 M1A M1B MX
ALL 259 36 6 1 26
subtype1 23 2 0 0 2
subtype2 47 2 3 0 5
subtype3 49 7 3 0 4
subtype4 140 25 0 1 15

Figure S57.  Get High-res Image Clustering Approach #6: 'RPPA cHierClus subtypes' versus Clinical Feature #6: 'PATHOLOGY.M.STAGE'

'RPPA cHierClus subtypes' versus 'GENDER'

P value = 0.261 (Fisher's exact test), Q value = 1

Table S64.  Clustering Approach #6: 'RPPA cHierClus subtypes' versus Clinical Feature #7: 'GENDER'

nPatients FEMALE MALE
ALL 155 176
subtype1 17 12
subtype2 21 36
subtype3 30 34
subtype4 87 94

Figure S58.  Get High-res Image Clustering Approach #6: 'RPPA cHierClus subtypes' versus Clinical Feature #7: 'GENDER'

'RPPA cHierClus subtypes' versus 'HISTOLOGICAL.TYPE'

P value = 0.268 (Fisher's exact test), Q value = 1

Table S65.  Clustering Approach #6: 'RPPA cHierClus subtypes' versus Clinical Feature #8: 'HISTOLOGICAL.TYPE'

nPatients COLON ADENOCARCINOMA COLON MUCINOUS ADENOCARCINOMA
ALL 293 38
subtype1 26 3
subtype2 47 10
subtype3 55 9
subtype4 165 16

Figure S59.  Get High-res Image Clustering Approach #6: 'RPPA cHierClus subtypes' versus Clinical Feature #8: 'HISTOLOGICAL.TYPE'

'RPPA cHierClus subtypes' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 0.32 (Fisher's exact test), Q value = 1

Table S66.  Clustering Approach #6: 'RPPA cHierClus subtypes' versus Clinical Feature #9: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients NO YES
ALL 3 328
subtype1 0 29
subtype2 0 57
subtype3 2 62
subtype4 1 180

Figure S60.  Get High-res Image Clustering Approach #6: 'RPPA cHierClus subtypes' versus Clinical Feature #9: 'RADIATIONS.RADIATION.REGIMENINDICATION'

'RPPA cHierClus subtypes' versus 'COMPLETENESS.OF.RESECTION'

P value = 0.217 (Chi-square test), Q value = 1

Table S67.  Clustering Approach #6: 'RPPA cHierClus subtypes' versus Clinical Feature #10: 'COMPLETENESS.OF.RESECTION'

nPatients R0 R2 RX
ALL 239 16 16
subtype1 21 2 2
subtype2 46 0 2
subtype3 48 1 2
subtype4 124 13 10

Figure S61.  Get High-res Image Clustering Approach #6: 'RPPA cHierClus subtypes' versus Clinical Feature #10: 'COMPLETENESS.OF.RESECTION'

'RPPA cHierClus subtypes' versus 'NUMBER.OF.LYMPH.NODES'

P value = 0.0461 (ANOVA), Q value = 1

Table S68.  Clustering Approach #6: 'RPPA cHierClus subtypes' versus Clinical Feature #11: 'NUMBER.OF.LYMPH.NODES'

nPatients Mean (Std.Dev)
ALL 311 2.0 (4.5)
subtype1 27 1.3 (2.5)
subtype2 54 1.1 (2.7)
subtype3 60 3.2 (7.4)
subtype4 170 1.9 (3.6)

Figure S62.  Get High-res Image Clustering Approach #6: 'RPPA cHierClus subtypes' versus Clinical Feature #11: 'NUMBER.OF.LYMPH.NODES'

Clustering Approach #7: 'RNAseq CNMF subtypes'

Table S69.  Description of clustering approach #7: 'RNAseq CNMF subtypes'

Cluster Labels 1 2 3 4 5
Number of samples 35 114 72 90 119
'RNAseq CNMF subtypes' versus 'Time to Death'

P value = 0.0434 (logrank test), Q value = 1

Table S70.  Clustering Approach #7: 'RNAseq CNMF subtypes' versus Clinical Feature #1: 'Time to Death'

nPatients nDeath Duration Range (Median), Month
ALL 391 82 0.1 - 140.4 (17.0)
subtype1 32 1 0.1 - 107.7 (25.1)
subtype2 105 29 0.1 - 140.4 (15.8)
subtype3 71 15 0.1 - 100.0 (12.1)
subtype4 85 15 0.7 - 135.7 (15.6)
subtype5 98 22 0.9 - 83.8 (22.0)

Figure S63.  Get High-res Image Clustering Approach #7: 'RNAseq CNMF subtypes' versus Clinical Feature #1: 'Time to Death'

'RNAseq CNMF subtypes' versus 'AGE'

P value = 0.00673 (ANOVA), Q value = 0.73

Table S71.  Clustering Approach #7: 'RNAseq CNMF subtypes' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 429 67.2 (12.9)
subtype1 35 65.7 (12.6)
subtype2 114 65.3 (12.4)
subtype3 72 64.1 (12.9)
subtype4 89 69.3 (13.6)
subtype5 119 69.7 (12.5)

Figure S64.  Get High-res Image Clustering Approach #7: 'RNAseq CNMF subtypes' versus Clinical Feature #2: 'AGE'

'RNAseq CNMF subtypes' versus 'NEOPLASM.DISEASESTAGE'

P value = 0.0281 (Chi-square test), Q value = 1

Table S72.  Clustering Approach #7: 'RNAseq CNMF subtypes' versus Clinical Feature #3: 'NEOPLASM.DISEASESTAGE'

nPatients STAGE I STAGE IA STAGE II STAGE IIA STAGE IIB STAGE IIC STAGE III STAGE IIIA STAGE IIIB STAGE IIIC STAGE IV STAGE IVA STAGE IVB
ALL 71 1 32 125 9 1 22 13 52 36 42 16 1
subtype1 6 0 2 10 0 0 4 3 4 2 1 3 0
subtype2 18 0 5 30 0 1 4 4 16 8 15 8 0
subtype3 7 0 5 23 1 0 2 2 10 9 8 3 0
subtype4 21 1 12 30 4 0 3 0 11 3 2 1 1
subtype5 19 0 8 32 4 0 9 4 11 14 16 1 0

Figure S65.  Get High-res Image Clustering Approach #7: 'RNAseq CNMF subtypes' versus Clinical Feature #3: 'NEOPLASM.DISEASESTAGE'

'RNAseq CNMF subtypes' versus 'PATHOLOGY.T.STAGE'

P value = 0.495 (Chi-square test), Q value = 1

Table S73.  Clustering Approach #7: 'RNAseq CNMF subtypes' versus Clinical Feature #4: 'PATHOLOGY.T.STAGE'

nPatients T0+T1 T2 T3 T4
ALL 11 75 294 49
subtype1 1 6 25 3
subtype2 2 24 75 13
subtype3 1 6 51 14
subtype4 3 18 60 8
subtype5 4 21 83 11

Figure S66.  Get High-res Image Clustering Approach #7: 'RNAseq CNMF subtypes' versus Clinical Feature #4: 'PATHOLOGY.T.STAGE'

'RNAseq CNMF subtypes' versus 'PATHOLOGY.N.STAGE'

P value = 0.00434 (Chi-square test), Q value = 0.48

Table S74.  Clustering Approach #7: 'RNAseq CNMF subtypes' versus Clinical Feature #5: 'PATHOLOGY.N.STAGE'

nPatients N0 N1 N2
ALL 254 101 74
subtype1 22 10 3
subtype2 62 35 16
subtype3 37 18 17
subtype4 68 13 9
subtype5 65 25 29

Figure S67.  Get High-res Image Clustering Approach #7: 'RNAseq CNMF subtypes' versus Clinical Feature #5: 'PATHOLOGY.N.STAGE'

'RNAseq CNMF subtypes' versus 'PATHOLOGY.M.STAGE'

P value = 0.00106 (Chi-square test), Q value = 0.12

Table S75.  Clustering Approach #7: 'RNAseq CNMF subtypes' versus Clinical Feature #6: 'PATHOLOGY.M.STAGE'

nPatients M0 M1 M1A M1B MX
ALL 323 50 7 1 42
subtype1 29 2 1 0 3
subtype2 73 19 4 0 17
subtype3 50 10 1 0 9
subtype4 72 3 0 1 13
subtype5 99 16 1 0 0

Figure S68.  Get High-res Image Clustering Approach #7: 'RNAseq CNMF subtypes' versus Clinical Feature #6: 'PATHOLOGY.M.STAGE'

'RNAseq CNMF subtypes' versus 'GENDER'

P value = 0.105 (Chi-square test), Q value = 1

Table S76.  Clustering Approach #7: 'RNAseq CNMF subtypes' versus Clinical Feature #7: 'GENDER'

nPatients FEMALE MALE
ALL 202 228
subtype1 11 24
subtype2 53 61
subtype3 30 42
subtype4 42 48
subtype5 66 53

Figure S69.  Get High-res Image Clustering Approach #7: 'RNAseq CNMF subtypes' versus Clinical Feature #7: 'GENDER'

'RNAseq CNMF subtypes' versus 'HISTOLOGICAL.TYPE'

P value = 9.33e-09 (Chi-square test), Q value = 1.2e-06

Table S77.  Clustering Approach #7: 'RNAseq CNMF subtypes' versus Clinical Feature #8: 'HISTOLOGICAL.TYPE'

nPatients COLON ADENOCARCINOMA COLON MUCINOUS ADENOCARCINOMA
ALL 372 56
subtype1 33 2
subtype2 112 2
subtype3 59 13
subtype4 62 28
subtype5 106 11

Figure S70.  Get High-res Image Clustering Approach #7: 'RNAseq CNMF subtypes' versus Clinical Feature #8: 'HISTOLOGICAL.TYPE'

'RNAseq CNMF subtypes' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 0.358 (Chi-square test), Q value = 1

Table S78.  Clustering Approach #7: 'RNAseq CNMF subtypes' versus Clinical Feature #9: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients NO YES
ALL 3 427
subtype1 1 34
subtype2 1 113
subtype3 1 71
subtype4 0 90
subtype5 0 119

Figure S71.  Get High-res Image Clustering Approach #7: 'RNAseq CNMF subtypes' versus Clinical Feature #9: 'RADIATIONS.RADIATION.REGIMENINDICATION'

'RNAseq CNMF subtypes' versus 'COMPLETENESS.OF.RESECTION'

P value = 0.00331 (Chi-square test), Q value = 0.37

Table S79.  Clustering Approach #7: 'RNAseq CNMF subtypes' versus Clinical Feature #10: 'COMPLETENESS.OF.RESECTION'

nPatients R0 R1 R2 RX
ALL 303 3 23 24
subtype1 27 1 1 2
subtype2 67 0 8 7
subtype3 50 0 1 6
subtype4 59 1 0 9
subtype5 100 1 13 0

Figure S72.  Get High-res Image Clustering Approach #7: 'RNAseq CNMF subtypes' versus Clinical Feature #10: 'COMPLETENESS.OF.RESECTION'

'RNAseq CNMF subtypes' versus 'NUMBER.OF.LYMPH.NODES'

P value = 0.0337 (ANOVA), Q value = 1

Table S80.  Clustering Approach #7: 'RNAseq CNMF subtypes' versus Clinical Feature #11: 'NUMBER.OF.LYMPH.NODES'

nPatients Mean (Std.Dev)
ALL 406 2.0 (4.4)
subtype1 35 1.3 (2.8)
subtype2 106 1.9 (4.1)
subtype3 66 3.2 (7.4)
subtype4 81 1.0 (2.5)
subtype5 118 2.3 (3.9)

Figure S73.  Get High-res Image Clustering Approach #7: 'RNAseq CNMF subtypes' versus Clinical Feature #11: 'NUMBER.OF.LYMPH.NODES'

Clustering Approach #8: 'RNAseq cHierClus subtypes'

Table S81.  Description of clustering approach #8: 'RNAseq cHierClus subtypes'

Cluster Labels 1 2 3
Number of samples 171 97 162
'RNAseq cHierClus subtypes' versus 'Time to Death'

P value = 0.801 (logrank test), Q value = 1

Table S82.  Clustering Approach #8: 'RNAseq cHierClus subtypes' versus Clinical Feature #1: 'Time to Death'

nPatients nDeath Duration Range (Median), Month
ALL 391 82 0.1 - 140.4 (17.0)
subtype1 139 28 0.9 - 83.8 (24.0)
subtype2 94 22 0.1 - 135.7 (15.0)
subtype3 158 32 0.1 - 140.4 (14.9)

Figure S74.  Get High-res Image Clustering Approach #8: 'RNAseq cHierClus subtypes' versus Clinical Feature #1: 'Time to Death'

'RNAseq cHierClus subtypes' versus 'AGE'

P value = 0.000782 (ANOVA), Q value = 0.091

Table S83.  Clustering Approach #8: 'RNAseq cHierClus subtypes' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 429 67.2 (12.9)
subtype1 171 70.0 (12.2)
subtype2 96 65.6 (14.2)
subtype3 162 65.1 (12.4)

Figure S75.  Get High-res Image Clustering Approach #8: 'RNAseq cHierClus subtypes' versus Clinical Feature #2: 'AGE'

'RNAseq cHierClus subtypes' versus 'NEOPLASM.DISEASESTAGE'

P value = 0.0401 (Chi-square test), Q value = 1

Table S84.  Clustering Approach #8: 'RNAseq cHierClus subtypes' versus Clinical Feature #3: 'NEOPLASM.DISEASESTAGE'

nPatients STAGE I STAGE IA STAGE II STAGE IIA STAGE IIB STAGE IIC STAGE III STAGE IIIA STAGE IIIB STAGE IIIC STAGE IV STAGE IVA STAGE IVB
ALL 71 1 32 125 9 1 22 13 52 36 42 16 1
subtype1 30 0 13 48 6 0 12 5 15 16 24 1 0
subtype2 18 1 8 31 2 0 4 3 13 8 5 2 1
subtype3 23 0 11 46 1 1 6 5 24 12 13 13 0

Figure S76.  Get High-res Image Clustering Approach #8: 'RNAseq cHierClus subtypes' versus Clinical Feature #3: 'NEOPLASM.DISEASESTAGE'

'RNAseq cHierClus subtypes' versus 'PATHOLOGY.T.STAGE'

P value = 0.947 (Chi-square test), Q value = 1

Table S85.  Clustering Approach #8: 'RNAseq cHierClus subtypes' versus Clinical Feature #4: 'PATHOLOGY.T.STAGE'

nPatients T0+T1 T2 T3 T4
ALL 11 75 294 49
subtype1 5 33 116 17
subtype2 3 16 65 12
subtype3 3 26 113 20

Figure S77.  Get High-res Image Clustering Approach #8: 'RNAseq cHierClus subtypes' versus Clinical Feature #4: 'PATHOLOGY.T.STAGE'

'RNAseq cHierClus subtypes' versus 'PATHOLOGY.N.STAGE'

P value = 0.346 (Chi-square test), Q value = 1

Table S86.  Clustering Approach #8: 'RNAseq cHierClus subtypes' versus Clinical Feature #5: 'PATHOLOGY.N.STAGE'

nPatients N0 N1 N2
ALL 254 101 74
subtype1 101 35 35
subtype2 62 21 14
subtype3 91 45 25

Figure S78.  Get High-res Image Clustering Approach #8: 'RNAseq cHierClus subtypes' versus Clinical Feature #5: 'PATHOLOGY.N.STAGE'

'RNAseq cHierClus subtypes' versus 'PATHOLOGY.M.STAGE'

P value = 3.07e-07 (Chi-square test), Q value = 3.9e-05

Table S87.  Clustering Approach #8: 'RNAseq cHierClus subtypes' versus Clinical Feature #6: 'PATHOLOGY.M.STAGE'

nPatients M0 M1 M1A M1B MX
ALL 323 50 7 1 42
subtype1 143 24 1 0 0
subtype2 71 6 0 1 18
subtype3 109 20 6 0 24

Figure S79.  Get High-res Image Clustering Approach #8: 'RNAseq cHierClus subtypes' versus Clinical Feature #6: 'PATHOLOGY.M.STAGE'

'RNAseq cHierClus subtypes' versus 'GENDER'

P value = 0.172 (Fisher's exact test), Q value = 1

Table S88.  Clustering Approach #8: 'RNAseq cHierClus subtypes' versus Clinical Feature #7: 'GENDER'

nPatients FEMALE MALE
ALL 202 228
subtype1 88 83
subtype2 47 50
subtype3 67 95

Figure S80.  Get High-res Image Clustering Approach #8: 'RNAseq cHierClus subtypes' versus Clinical Feature #7: 'GENDER'

'RNAseq cHierClus subtypes' versus 'HISTOLOGICAL.TYPE'

P value = 0.00216 (Fisher's exact test), Q value = 0.24

Table S89.  Clustering Approach #8: 'RNAseq cHierClus subtypes' versus Clinical Feature #8: 'HISTOLOGICAL.TYPE'

nPatients COLON ADENOCARCINOMA COLON MUCINOUS ADENOCARCINOMA
ALL 372 56
subtype1 145 24
subtype2 76 21
subtype3 151 11

Figure S81.  Get High-res Image Clustering Approach #8: 'RNAseq cHierClus subtypes' versus Clinical Feature #8: 'HISTOLOGICAL.TYPE'

'RNAseq cHierClus subtypes' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 0.0641 (Fisher's exact test), Q value = 1

Table S90.  Clustering Approach #8: 'RNAseq cHierClus subtypes' versus Clinical Feature #9: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients NO YES
ALL 3 427
subtype1 0 171
subtype2 0 97
subtype3 3 159

Figure S82.  Get High-res Image Clustering Approach #8: 'RNAseq cHierClus subtypes' versus Clinical Feature #9: 'RADIATIONS.RADIATION.REGIMENINDICATION'

'RNAseq cHierClus subtypes' versus 'COMPLETENESS.OF.RESECTION'

P value = 4.26e-08 (Chi-square test), Q value = 5.4e-06

Table S91.  Clustering Approach #8: 'RNAseq cHierClus subtypes' versus Clinical Feature #10: 'COMPLETENESS.OF.RESECTION'

nPatients R0 R1 R2 RX
ALL 303 3 23 24
subtype1 145 1 20 0
subtype2 57 2 1 13
subtype3 101 0 2 11

Figure S83.  Get High-res Image Clustering Approach #8: 'RNAseq cHierClus subtypes' versus Clinical Feature #10: 'COMPLETENESS.OF.RESECTION'

'RNAseq cHierClus subtypes' versus 'NUMBER.OF.LYMPH.NODES'

P value = 0.525 (ANOVA), Q value = 1

Table S92.  Clustering Approach #8: 'RNAseq cHierClus subtypes' versus Clinical Feature #11: 'NUMBER.OF.LYMPH.NODES'

nPatients Mean (Std.Dev)
ALL 406 2.0 (4.4)
subtype1 169 2.2 (4.4)
subtype2 86 1.5 (2.9)
subtype3 151 2.1 (5.1)

Figure S84.  Get High-res Image Clustering Approach #8: 'RNAseq cHierClus subtypes' versus Clinical Feature #11: 'NUMBER.OF.LYMPH.NODES'

Clustering Approach #9: 'MIRSEQ CNMF'

Table S93.  Description of clustering approach #9: 'MIRSEQ CNMF'

Cluster Labels 1 2 3
Number of samples 160 66 180
'MIRSEQ CNMF' versus 'Time to Death'

P value = 0.211 (logrank test), Q value = 1

Table S94.  Clustering Approach #9: 'MIRSEQ CNMF' versus Clinical Feature #1: 'Time to Death'

nPatients nDeath Duration Range (Median), Month
ALL 366 77 0.1 - 140.4 (17.0)
subtype1 155 29 0.1 - 140.4 (15.6)
subtype2 66 13 0.1 - 100.0 (11.8)
subtype3 145 35 0.9 - 83.8 (24.0)

Figure S85.  Get High-res Image Clustering Approach #9: 'MIRSEQ CNMF' versus Clinical Feature #1: 'Time to Death'

'MIRSEQ CNMF' versus 'AGE'

P value = 0.000278 (ANOVA), Q value = 0.033

Table S95.  Clustering Approach #9: 'MIRSEQ CNMF' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 405 67.3 (13.0)
subtype1 159 66.5 (12.4)
subtype2 66 62.6 (14.4)
subtype3 180 69.9 (12.5)

Figure S86.  Get High-res Image Clustering Approach #9: 'MIRSEQ CNMF' versus Clinical Feature #2: 'AGE'

'MIRSEQ CNMF' versus 'NEOPLASM.DISEASESTAGE'

P value = 0.167 (Chi-square test), Q value = 1

Table S96.  Clustering Approach #9: 'MIRSEQ CNMF' versus Clinical Feature #3: 'NEOPLASM.DISEASESTAGE'

nPatients STAGE I STAGE IA STAGE II STAGE IIA STAGE IIB STAGE IIC STAGE III STAGE IIIA STAGE IIIB STAGE IIIC STAGE IV STAGE IVA STAGE IVB
ALL 66 1 33 115 8 1 22 12 48 32 42 16 1
subtype1 24 1 9 53 2 1 8 5 23 11 11 7 1
subtype2 7 0 6 18 0 0 2 3 10 8 4 4 0
subtype3 35 0 18 44 6 0 12 4 15 13 27 5 0

Figure S87.  Get High-res Image Clustering Approach #9: 'MIRSEQ CNMF' versus Clinical Feature #3: 'NEOPLASM.DISEASESTAGE'

'MIRSEQ CNMF' versus 'PATHOLOGY.T.STAGE'

P value = 0.358 (Chi-square test), Q value = 1

Table S97.  Clustering Approach #9: 'MIRSEQ CNMF' versus Clinical Feature #4: 'PATHOLOGY.T.STAGE'

nPatients T0+T1 T2 T3 T4
ALL 11 69 279 46
subtype1 5 24 115 15
subtype2 0 9 46 11
subtype3 6 36 118 20

Figure S88.  Get High-res Image Clustering Approach #9: 'MIRSEQ CNMF' versus Clinical Feature #4: 'PATHOLOGY.T.STAGE'

'MIRSEQ CNMF' versus 'PATHOLOGY.N.STAGE'

P value = 0.312 (Chi-square test), Q value = 1

Table S98.  Clustering Approach #9: 'MIRSEQ CNMF' versus Clinical Feature #5: 'PATHOLOGY.N.STAGE'

nPatients N0 N1 N2
ALL 239 95 71
subtype1 98 39 22
subtype2 33 19 14
subtype3 108 37 35

Figure S89.  Get High-res Image Clustering Approach #9: 'MIRSEQ CNMF' versus Clinical Feature #5: 'PATHOLOGY.N.STAGE'

'MIRSEQ CNMF' versus 'PATHOLOGY.M.STAGE'

P value = 1.02e-05 (Chi-square test), Q value = 0.0012

Table S99.  Clustering Approach #9: 'MIRSEQ CNMF' versus Clinical Feature #6: 'PATHOLOGY.M.STAGE'

nPatients M0 M1 M1A M1B MX
ALL 305 50 7 1 36
subtype1 113 12 5 1 26
subtype2 48 8 0 0 9
subtype3 144 30 2 0 1

Figure S90.  Get High-res Image Clustering Approach #9: 'MIRSEQ CNMF' versus Clinical Feature #6: 'PATHOLOGY.M.STAGE'

'MIRSEQ CNMF' versus 'GENDER'

P value = 0.441 (Fisher's exact test), Q value = 1

Table S100.  Clustering Approach #9: 'MIRSEQ CNMF' versus Clinical Feature #7: 'GENDER'

nPatients FEMALE MALE
ALL 191 215
subtype1 74 86
subtype2 27 39
subtype3 90 90

Figure S91.  Get High-res Image Clustering Approach #9: 'MIRSEQ CNMF' versus Clinical Feature #7: 'GENDER'

'MIRSEQ CNMF' versus 'HISTOLOGICAL.TYPE'

P value = 0.095 (Fisher's exact test), Q value = 1

Table S101.  Clustering Approach #9: 'MIRSEQ CNMF' versus Clinical Feature #8: 'HISTOLOGICAL.TYPE'

nPatients COLON ADENOCARCINOMA COLON MUCINOUS ADENOCARCINOMA
ALL 351 53
subtype1 145 15
subtype2 53 13
subtype3 153 25

Figure S92.  Get High-res Image Clustering Approach #9: 'MIRSEQ CNMF' versus Clinical Feature #8: 'HISTOLOGICAL.TYPE'

'MIRSEQ CNMF' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 0.07 (Fisher's exact test), Q value = 1

Table S102.  Clustering Approach #9: 'MIRSEQ CNMF' versus Clinical Feature #9: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients NO YES
ALL 3 403
subtype1 0 160
subtype2 2 64
subtype3 1 179

Figure S93.  Get High-res Image Clustering Approach #9: 'MIRSEQ CNMF' versus Clinical Feature #9: 'RADIATIONS.RADIATION.REGIMENINDICATION'

'MIRSEQ CNMF' versus 'COMPLETENESS.OF.RESECTION'

P value = 7.93e-06 (Chi-square test), Q value = 0.00097

Table S103.  Clustering Approach #9: 'MIRSEQ CNMF' versus Clinical Feature #10: 'COMPLETENESS.OF.RESECTION'

nPatients R0 R1 R2 RX
ALL 280 3 25 22
subtype1 92 1 2 15
subtype2 43 0 0 5
subtype3 145 2 23 2

Figure S94.  Get High-res Image Clustering Approach #9: 'MIRSEQ CNMF' versus Clinical Feature #10: 'COMPLETENESS.OF.RESECTION'

'MIRSEQ CNMF' versus 'NUMBER.OF.LYMPH.NODES'

P value = 0.0625 (ANOVA), Q value = 1

Table S104.  Clustering Approach #9: 'MIRSEQ CNMF' versus Clinical Feature #11: 'NUMBER.OF.LYMPH.NODES'

nPatients Mean (Std.Dev)
ALL 382 2.0 (4.5)
subtype1 146 1.6 (3.0)
subtype2 61 3.2 (8.0)
subtype3 175 2.0 (3.8)

Figure S95.  Get High-res Image Clustering Approach #9: 'MIRSEQ CNMF' versus Clinical Feature #11: 'NUMBER.OF.LYMPH.NODES'

Clustering Approach #10: 'MIRSEQ CHIERARCHICAL'

Table S105.  Description of clustering approach #10: 'MIRSEQ CHIERARCHICAL'

Cluster Labels 1 2 3
Number of samples 81 182 143
'MIRSEQ CHIERARCHICAL' versus 'Time to Death'

P value = 0.321 (logrank test), Q value = 1

Table S106.  Clustering Approach #10: 'MIRSEQ CHIERARCHICAL' versus Clinical Feature #1: 'Time to Death'

nPatients nDeath Duration Range (Median), Month
ALL 366 77 0.1 - 140.4 (17.0)
subtype1 77 15 0.2 - 135.7 (20.2)
subtype2 149 36 0.1 - 83.8 (24.0)
subtype3 140 26 0.1 - 140.4 (13.5)

Figure S96.  Get High-res Image Clustering Approach #10: 'MIRSEQ CHIERARCHICAL' versus Clinical Feature #1: 'Time to Death'

'MIRSEQ CHIERARCHICAL' versus 'AGE'

P value = 0.00212 (ANOVA), Q value = 0.24

Table S107.  Clustering Approach #10: 'MIRSEQ CHIERARCHICAL' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 405 67.3 (13.0)
subtype1 80 67.2 (13.0)
subtype2 182 69.6 (12.5)
subtype3 143 64.5 (13.3)

Figure S97.  Get High-res Image Clustering Approach #10: 'MIRSEQ CHIERARCHICAL' versus Clinical Feature #2: 'AGE'

'MIRSEQ CHIERARCHICAL' versus 'NEOPLASM.DISEASESTAGE'

P value = 0.0107 (Chi-square test), Q value = 1

Table S108.  Clustering Approach #10: 'MIRSEQ CHIERARCHICAL' versus Clinical Feature #3: 'NEOPLASM.DISEASESTAGE'

nPatients STAGE I STAGE IA STAGE II STAGE IIA STAGE IIB STAGE IIC STAGE III STAGE IIIA STAGE IIIB STAGE IIIC STAGE IV STAGE IVA STAGE IVB
ALL 66 1 33 115 8 1 22 12 48 32 42 16 1
subtype1 13 0 5 32 3 1 3 1 7 7 3 3 1
subtype2 35 0 17 44 4 0 14 4 16 14 28 5 0
subtype3 18 1 11 39 1 0 5 7 25 11 11 8 0

Figure S98.  Get High-res Image Clustering Approach #10: 'MIRSEQ CHIERARCHICAL' versus Clinical Feature #3: 'NEOPLASM.DISEASESTAGE'

'MIRSEQ CHIERARCHICAL' versus 'PATHOLOGY.T.STAGE'

P value = 0.659 (Chi-square test), Q value = 1

Table S109.  Clustering Approach #10: 'MIRSEQ CHIERARCHICAL' versus Clinical Feature #4: 'PATHOLOGY.T.STAGE'

nPatients T0+T1 T2 T3 T4
ALL 11 69 279 46
subtype1 3 14 55 9
subtype2 6 36 121 19
subtype3 2 19 103 18

Figure S99.  Get High-res Image Clustering Approach #10: 'MIRSEQ CHIERARCHICAL' versus Clinical Feature #4: 'PATHOLOGY.T.STAGE'

'MIRSEQ CHIERARCHICAL' versus 'PATHOLOGY.N.STAGE'

P value = 0.0252 (Chi-square test), Q value = 1

Table S110.  Clustering Approach #10: 'MIRSEQ CHIERARCHICAL' versus Clinical Feature #5: 'PATHOLOGY.N.STAGE'

nPatients N0 N1 N2
ALL 239 95 71
subtype1 57 10 13
subtype2 105 41 36
subtype3 77 44 22

Figure S100.  Get High-res Image Clustering Approach #10: 'MIRSEQ CHIERARCHICAL' versus Clinical Feature #5: 'PATHOLOGY.N.STAGE'

'MIRSEQ CHIERARCHICAL' versus 'PATHOLOGY.M.STAGE'

P value = 2.16e-06 (Chi-square test), Q value = 0.00027

Table S111.  Clustering Approach #10: 'MIRSEQ CHIERARCHICAL' versus Clinical Feature #6: 'PATHOLOGY.M.STAGE'

nPatients M0 M1 M1A M1B MX
ALL 305 50 7 1 36
subtype1 63 4 2 1 10
subtype2 145 31 2 0 1
subtype3 97 15 3 0 25

Figure S101.  Get High-res Image Clustering Approach #10: 'MIRSEQ CHIERARCHICAL' versus Clinical Feature #6: 'PATHOLOGY.M.STAGE'

'MIRSEQ CHIERARCHICAL' versus 'GENDER'

P value = 0.312 (Fisher's exact test), Q value = 1

Table S112.  Clustering Approach #10: 'MIRSEQ CHIERARCHICAL' versus Clinical Feature #7: 'GENDER'

nPatients FEMALE MALE
ALL 191 215
subtype1 34 47
subtype2 93 89
subtype3 64 79

Figure S102.  Get High-res Image Clustering Approach #10: 'MIRSEQ CHIERARCHICAL' versus Clinical Feature #7: 'GENDER'

'MIRSEQ CHIERARCHICAL' versus 'HISTOLOGICAL.TYPE'

P value = 1 (Fisher's exact test), Q value = 1

Table S113.  Clustering Approach #10: 'MIRSEQ CHIERARCHICAL' versus Clinical Feature #8: 'HISTOLOGICAL.TYPE'

nPatients COLON ADENOCARCINOMA COLON MUCINOUS ADENOCARCINOMA
ALL 351 53
subtype1 71 10
subtype2 156 24
subtype3 124 19

Figure S103.  Get High-res Image Clustering Approach #10: 'MIRSEQ CHIERARCHICAL' versus Clinical Feature #8: 'HISTOLOGICAL.TYPE'

'MIRSEQ CHIERARCHICAL' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 0.597 (Fisher's exact test), Q value = 1

Table S114.  Clustering Approach #10: 'MIRSEQ CHIERARCHICAL' versus Clinical Feature #9: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients NO YES
ALL 3 403
subtype1 0 81
subtype2 1 181
subtype3 2 141

Figure S104.  Get High-res Image Clustering Approach #10: 'MIRSEQ CHIERARCHICAL' versus Clinical Feature #9: 'RADIATIONS.RADIATION.REGIMENINDICATION'

'MIRSEQ CHIERARCHICAL' versus 'COMPLETENESS.OF.RESECTION'

P value = 7.85e-06 (Chi-square test), Q value = 0.00097

Table S115.  Clustering Approach #10: 'MIRSEQ CHIERARCHICAL' versus Clinical Feature #10: 'COMPLETENESS.OF.RESECTION'

nPatients R0 R1 R2 RX
ALL 280 3 25 22
subtype1 42 0 2 6
subtype2 147 2 23 2
subtype3 91 1 0 14

Figure S105.  Get High-res Image Clustering Approach #10: 'MIRSEQ CHIERARCHICAL' versus Clinical Feature #10: 'COMPLETENESS.OF.RESECTION'

'MIRSEQ CHIERARCHICAL' versus 'NUMBER.OF.LYMPH.NODES'

P value = 0.524 (ANOVA), Q value = 1

Table S116.  Clustering Approach #10: 'MIRSEQ CHIERARCHICAL' versus Clinical Feature #11: 'NUMBER.OF.LYMPH.NODES'

nPatients Mean (Std.Dev)
ALL 382 2.0 (4.5)
subtype1 74 1.5 (3.0)
subtype2 177 2.2 (4.4)
subtype3 131 2.2 (5.4)

Figure S106.  Get High-res Image Clustering Approach #10: 'MIRSEQ CHIERARCHICAL' versus Clinical Feature #11: 'NUMBER.OF.LYMPH.NODES'

Clustering Approach #11: 'MIRseq Mature CNMF subtypes'

Table S117.  Description of clustering approach #11: 'MIRseq Mature CNMF subtypes'

Cluster Labels 1 2 3
Number of samples 79 78 63
'MIRseq Mature CNMF subtypes' versus 'Time to Death'

P value = 0.161 (logrank test), Q value = 1

Table S118.  Clustering Approach #11: 'MIRseq Mature CNMF subtypes' versus Clinical Feature #1: 'Time to Death'

nPatients nDeath Duration Range (Median), Month
ALL 214 42 0.1 - 140.4 (14.0)
subtype1 75 15 0.1 - 140.4 (16.0)
subtype2 76 15 0.1 - 135.7 (14.0)
subtype3 63 12 0.2 - 62.8 (12.1)

Figure S107.  Get High-res Image Clustering Approach #11: 'MIRseq Mature CNMF subtypes' versus Clinical Feature #1: 'Time to Death'

'MIRseq Mature CNMF subtypes' versus 'AGE'

P value = 0.122 (ANOVA), Q value = 1

Table S119.  Clustering Approach #11: 'MIRseq Mature CNMF subtypes' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 219 65.3 (13.2)
subtype1 79 66.7 (11.2)
subtype2 77 66.3 (13.9)
subtype3 63 62.5 (14.3)

Figure S108.  Get High-res Image Clustering Approach #11: 'MIRseq Mature CNMF subtypes' versus Clinical Feature #2: 'AGE'

'MIRseq Mature CNMF subtypes' versus 'NEOPLASM.DISEASESTAGE'

P value = 0.466 (Chi-square test), Q value = 1

Table S120.  Clustering Approach #11: 'MIRseq Mature CNMF subtypes' versus Clinical Feature #3: 'NEOPLASM.DISEASESTAGE'

nPatients STAGE I STAGE IA STAGE II STAGE IIA STAGE IIB STAGE IIC STAGE III STAGE IIIA STAGE IIIB STAGE IIIC STAGE IV STAGE IVA STAGE IVB
ALL 30 1 15 69 3 1 8 8 32 18 15 11 1
subtype1 10 0 4 25 0 1 5 4 9 8 6 3 0
subtype2 15 1 7 26 2 0 2 3 10 3 3 3 1
subtype3 5 0 4 18 1 0 1 1 13 7 6 5 0

Figure S109.  Get High-res Image Clustering Approach #11: 'MIRseq Mature CNMF subtypes' versus Clinical Feature #3: 'NEOPLASM.DISEASESTAGE'

'MIRseq Mature CNMF subtypes' versus 'PATHOLOGY.T.STAGE'

P value = 0.205 (Chi-square test), Q value = 1

Table S121.  Clustering Approach #11: 'MIRseq Mature CNMF subtypes' versus Clinical Feature #4: 'PATHOLOGY.T.STAGE'

nPatients T0+T1 T2 T3 T4
ALL 5 31 157 26
subtype1 2 12 58 7
subtype2 2 15 53 7
subtype3 1 4 46 12

Figure S110.  Get High-res Image Clustering Approach #11: 'MIRseq Mature CNMF subtypes' versus Clinical Feature #4: 'PATHOLOGY.T.STAGE'

'MIRseq Mature CNMF subtypes' versus 'PATHOLOGY.N.STAGE'

P value = 0.0279 (Chi-square test), Q value = 1

Table S122.  Clustering Approach #11: 'MIRseq Mature CNMF subtypes' versus Clinical Feature #5: 'PATHOLOGY.N.STAGE'

nPatients N0 N1 N2
ALL 129 55 35
subtype1 45 20 14
subtype2 55 16 6
subtype3 29 19 15

Figure S111.  Get High-res Image Clustering Approach #11: 'MIRseq Mature CNMF subtypes' versus Clinical Feature #5: 'PATHOLOGY.N.STAGE'

'MIRseq Mature CNMF subtypes' versus 'PATHOLOGY.M.STAGE'

P value = 0.459 (Chi-square test), Q value = 1

Table S123.  Clustering Approach #11: 'MIRseq Mature CNMF subtypes' versus Clinical Feature #6: 'PATHOLOGY.M.STAGE'

nPatients M0 M1 M1A M1B MX
ALL 154 20 5 1 36
subtype1 59 7 2 0 10
subtype2 55 4 1 1 16
subtype3 40 9 2 0 10

Figure S112.  Get High-res Image Clustering Approach #11: 'MIRseq Mature CNMF subtypes' versus Clinical Feature #6: 'PATHOLOGY.M.STAGE'

'MIRseq Mature CNMF subtypes' versus 'GENDER'

P value = 0.312 (Fisher's exact test), Q value = 1

Table S124.  Clustering Approach #11: 'MIRseq Mature CNMF subtypes' versus Clinical Feature #7: 'GENDER'

nPatients FEMALE MALE
ALL 96 124
subtype1 30 49
subtype2 39 39
subtype3 27 36

Figure S113.  Get High-res Image Clustering Approach #11: 'MIRseq Mature CNMF subtypes' versus Clinical Feature #7: 'GENDER'

'MIRseq Mature CNMF subtypes' versus 'HISTOLOGICAL.TYPE'

P value = 6.9e-05 (Fisher's exact test), Q value = 0.0083

Table S125.  Clustering Approach #11: 'MIRseq Mature CNMF subtypes' versus Clinical Feature #8: 'HISTOLOGICAL.TYPE'

nPatients COLON ADENOCARCINOMA COLON MUCINOUS ADENOCARCINOMA
ALL 191 29
subtype1 78 1
subtype2 62 16
subtype3 51 12

Figure S114.  Get High-res Image Clustering Approach #11: 'MIRseq Mature CNMF subtypes' versus Clinical Feature #8: 'HISTOLOGICAL.TYPE'

'MIRseq Mature CNMF subtypes' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 0.744 (Fisher's exact test), Q value = 1

Table S126.  Clustering Approach #11: 'MIRseq Mature CNMF subtypes' versus Clinical Feature #9: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients NO YES
ALL 2 218
subtype1 1 78
subtype2 0 78
subtype3 1 62

Figure S115.  Get High-res Image Clustering Approach #11: 'MIRseq Mature CNMF subtypes' versus Clinical Feature #9: 'RADIATIONS.RADIATION.REGIMENINDICATION'

'MIRseq Mature CNMF subtypes' versus 'COMPLETENESS.OF.RESECTION'

P value = 0.45 (Chi-square test), Q value = 1

Table S127.  Clustering Approach #11: 'MIRseq Mature CNMF subtypes' versus Clinical Feature #10: 'COMPLETENESS.OF.RESECTION'

nPatients R0 R1 R2 RX
ALL 128 1 2 20
subtype1 43 0 1 7
subtype2 43 1 1 10
subtype3 42 0 0 3

Figure S116.  Get High-res Image Clustering Approach #11: 'MIRseq Mature CNMF subtypes' versus Clinical Feature #10: 'COMPLETENESS.OF.RESECTION'

'MIRseq Mature CNMF subtypes' versus 'NUMBER.OF.LYMPH.NODES'

P value = 0.042 (ANOVA), Q value = 1

Table S128.  Clustering Approach #11: 'MIRseq Mature CNMF subtypes' versus Clinical Feature #11: 'NUMBER.OF.LYMPH.NODES'

nPatients Mean (Std.Dev)
ALL 200 2.0 (4.7)
subtype1 72 1.8 (3.1)
subtype2 69 1.1 (2.6)
subtype3 59 3.2 (7.3)

Figure S117.  Get High-res Image Clustering Approach #11: 'MIRseq Mature CNMF subtypes' versus Clinical Feature #11: 'NUMBER.OF.LYMPH.NODES'

Clustering Approach #12: 'MIRseq Mature cHierClus subtypes'

Table S129.  Description of clustering approach #12: 'MIRseq Mature cHierClus subtypes'

Cluster Labels 1 2 3
Number of samples 21 86 113
'MIRseq Mature cHierClus subtypes' versus 'Time to Death'

P value = 0.204 (logrank test), Q value = 1

Table S130.  Clustering Approach #12: 'MIRseq Mature cHierClus subtypes' versus Clinical Feature #1: 'Time to Death'

nPatients nDeath Duration Range (Median), Month
ALL 214 42 0.1 - 140.4 (14.0)
subtype1 20 3 0.1 - 139.2 (14.7)
subtype2 86 17 0.1 - 100.0 (12.0)
subtype3 108 22 0.1 - 140.4 (15.3)

Figure S118.  Get High-res Image Clustering Approach #12: 'MIRseq Mature cHierClus subtypes' versus Clinical Feature #1: 'Time to Death'

'MIRseq Mature cHierClus subtypes' versus 'AGE'

P value = 0.157 (ANOVA), Q value = 1

Table S131.  Clustering Approach #12: 'MIRseq Mature cHierClus subtypes' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 219 65.3 (13.2)
subtype1 21 65.7 (13.1)
subtype2 86 63.2 (14.0)
subtype3 112 66.9 (12.5)

Figure S119.  Get High-res Image Clustering Approach #12: 'MIRseq Mature cHierClus subtypes' versus Clinical Feature #2: 'AGE'

'MIRseq Mature cHierClus subtypes' versus 'NEOPLASM.DISEASESTAGE'

P value = 0.947 (Chi-square test), Q value = 1

Table S132.  Clustering Approach #12: 'MIRseq Mature cHierClus subtypes' versus Clinical Feature #3: 'NEOPLASM.DISEASESTAGE'

nPatients STAGE I STAGE IA STAGE II STAGE IIA STAGE IIB STAGE IIC STAGE III STAGE IIIA STAGE IIIB STAGE IIIC STAGE IV STAGE IVA STAGE IVB
ALL 30 1 15 69 3 1 8 8 32 18 15 11 1
subtype1 3 0 2 5 0 0 1 0 5 2 3 0 0
subtype2 10 0 7 25 1 0 2 3 14 9 6 6 0
subtype3 17 1 6 39 2 1 5 5 13 7 6 5 1

Figure S120.  Get High-res Image Clustering Approach #12: 'MIRseq Mature cHierClus subtypes' versus Clinical Feature #3: 'NEOPLASM.DISEASESTAGE'

'MIRseq Mature cHierClus subtypes' versus 'PATHOLOGY.T.STAGE'

P value = 0.723 (Chi-square test), Q value = 1

Table S133.  Clustering Approach #12: 'MIRseq Mature cHierClus subtypes' versus Clinical Feature #4: 'PATHOLOGY.T.STAGE'

nPatients T0+T1 T2 T3 T4
ALL 5 31 157 26
subtype1 0 3 15 3
subtype2 1 11 61 13
subtype3 4 17 81 10

Figure S121.  Get High-res Image Clustering Approach #12: 'MIRseq Mature cHierClus subtypes' versus Clinical Feature #4: 'PATHOLOGY.T.STAGE'

'MIRseq Mature cHierClus subtypes' versus 'PATHOLOGY.N.STAGE'

P value = 0.419 (Chi-square test), Q value = 1

Table S134.  Clustering Approach #12: 'MIRseq Mature cHierClus subtypes' versus Clinical Feature #5: 'PATHOLOGY.N.STAGE'

nPatients N0 N1 N2
ALL 129 55 35
subtype1 11 6 4
subtype2 45 26 15
subtype3 73 23 16

Figure S122.  Get High-res Image Clustering Approach #12: 'MIRseq Mature cHierClus subtypes' versus Clinical Feature #5: 'PATHOLOGY.N.STAGE'

'MIRseq Mature cHierClus subtypes' versus 'PATHOLOGY.M.STAGE'

P value = 0.86 (Chi-square test), Q value = 1

Table S135.  Clustering Approach #12: 'MIRseq Mature cHierClus subtypes' versus Clinical Feature #6: 'PATHOLOGY.M.STAGE'

nPatients M0 M1 M1A M1B MX
ALL 154 20 5 1 36
subtype1 14 3 0 0 4
subtype2 60 10 2 0 13
subtype3 80 7 3 1 19

Figure S123.  Get High-res Image Clustering Approach #12: 'MIRseq Mature cHierClus subtypes' versus Clinical Feature #6: 'PATHOLOGY.M.STAGE'

'MIRseq Mature cHierClus subtypes' versus 'GENDER'

P value = 0.865 (Fisher's exact test), Q value = 1

Table S136.  Clustering Approach #12: 'MIRseq Mature cHierClus subtypes' versus Clinical Feature #7: 'GENDER'

nPatients FEMALE MALE
ALL 96 124
subtype1 10 11
subtype2 36 50
subtype3 50 63

Figure S124.  Get High-res Image Clustering Approach #12: 'MIRseq Mature cHierClus subtypes' versus Clinical Feature #7: 'GENDER'

'MIRseq Mature cHierClus subtypes' versus 'HISTOLOGICAL.TYPE'

P value = 0.0703 (Fisher's exact test), Q value = 1

Table S137.  Clustering Approach #12: 'MIRseq Mature cHierClus subtypes' versus Clinical Feature #8: 'HISTOLOGICAL.TYPE'

nPatients COLON ADENOCARCINOMA COLON MUCINOUS ADENOCARCINOMA
ALL 191 29
subtype1 19 2
subtype2 69 17
subtype3 103 10

Figure S125.  Get High-res Image Clustering Approach #12: 'MIRseq Mature cHierClus subtypes' versus Clinical Feature #8: 'HISTOLOGICAL.TYPE'

'MIRseq Mature cHierClus subtypes' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 0.334 (Fisher's exact test), Q value = 1

Table S138.  Clustering Approach #12: 'MIRseq Mature cHierClus subtypes' versus Clinical Feature #9: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients NO YES
ALL 2 218
subtype1 0 21
subtype2 2 84
subtype3 0 113

Figure S126.  Get High-res Image Clustering Approach #12: 'MIRseq Mature cHierClus subtypes' versus Clinical Feature #9: 'RADIATIONS.RADIATION.REGIMENINDICATION'

'MIRseq Mature cHierClus subtypes' versus 'COMPLETENESS.OF.RESECTION'

P value = 0.445 (Chi-square test), Q value = 1

Table S139.  Clustering Approach #12: 'MIRseq Mature cHierClus subtypes' versus Clinical Feature #10: 'COMPLETENESS.OF.RESECTION'

nPatients R0 R1 R2 RX
ALL 128 1 2 20
subtype1 12 0 0 4
subtype2 58 0 0 7
subtype3 58 1 2 9

Figure S127.  Get High-res Image Clustering Approach #12: 'MIRseq Mature cHierClus subtypes' versus Clinical Feature #10: 'COMPLETENESS.OF.RESECTION'

'MIRseq Mature cHierClus subtypes' versus 'NUMBER.OF.LYMPH.NODES'

P value = 0.069 (ANOVA), Q value = 1

Table S140.  Clustering Approach #12: 'MIRseq Mature cHierClus subtypes' versus Clinical Feature #11: 'NUMBER.OF.LYMPH.NODES'

nPatients Mean (Std.Dev)
ALL 200 2.0 (4.7)
subtype1 17 4.3 (12.1)
subtype2 77 2.1 (3.7)
subtype3 106 1.5 (2.9)

Figure S128.  Get High-res Image Clustering Approach #12: 'MIRseq Mature cHierClus subtypes' versus Clinical Feature #11: 'NUMBER.OF.LYMPH.NODES'

Methods & Data
Input
  • Cluster data file = COAD-TP.mergedcluster.txt

  • Clinical data file = COAD-TP.merged_data.txt

  • Number of patients = 434

  • Number of clustering approaches = 12

  • Number of selected clinical features = 11

  • Exclude small clusters that include fewer than K patients, K = 3

Clustering approaches
CNMF clustering

consensus non-negative matrix factorization clustering approach (Brunet et al. 2004)

Consensus hierarchical clustering

Resampling-based clustering method (Monti et al. 2003)

Survival analysis

For survival clinical features, the Kaplan-Meier survival curves of tumors with and without gene mutations were plotted and the statistical significance P values were estimated by logrank test (Bland and Altman 2004) using the 'survdiff' function in R

ANOVA analysis

For continuous numerical clinical features, one-way analysis of variance (Howell 2002) was applied to compare the clinical values between tumor subtypes using 'anova' function in R

Chi-square test

For multi-class clinical features (nominal or ordinal), Chi-square tests (Greenwood and Nikulin 1996) were used to estimate the P values using the 'chisq.test' function in R

Fisher's exact test

For binary clinical features, two-tailed Fisher's exact tests (Fisher 1922) were used to estimate the P values using the 'fisher.test' function in R

Q value calculation

For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.

Download Results

In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.

References
[1] Brunet et al., Metagenes and molecular pattern discovery using matrix factorization, PNAS 101(12):4164-9 (2004)
[3] Bland and Altman, Statistics notes: The logrank test, BMJ 328(7447):1073 (2004)
[4] Howell, D, Statistical Methods for Psychology. (5th ed.), Duxbury Press:324-5 (2002)
[5] Greenwood and Nikulin, A guide to chi-squared testing, Wiley, New York. ISBN 047155779X (1996)
[6] Fisher, R.A., On the interpretation of chi-square from contingency tables, and the calculation of P, Journal of the Royal Statistical Society 85(1):87-94 (1922)
[7] Benjamini and Hochberg, Controlling the false discovery rate: a practical and powerful approach to multiple testing, Journal of the Royal Statistical Society Series B 59:289-300 (1995)